ArticleInterventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences2025
Middle meningeal artery embolization as a stand-alone treatment for primary and recurrent chronic subdural hematoma.
Article in Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Radiographic Course Following Middle Meningeal Artery Embolization for Chronic Subdural Hematoma.Journal of neuroendovascular therapy · 2026Review
Corrections and comments
- Expression of concern
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveChronic subdural hematoma (cSDH) is one of the most common neurosurgical emergencies. Due to high percentage of hematoma reaccumulation middle meningeal artery (MMA) embolization arose as an alternative treatment option. Aim of this retrospective study is to present single center results of 97 stand-alone embolization procedures done during 3-year period.MethodsProspectively maintained database of all patients who underwent MMA embolization from December 2021 to March 2025 was retrospectively analyzed. Seventy-five asymptomatic or mildly symptomatic patients with 97 hematomas were included; 72 MMA embolization procedures were done as primary treatment in 55 patients, whereas cSDH recurrency was main indication for 25 procedures in 20 patients. Primary and recurrent cSDH groups were compared using Chi-square test.ResultsMean follow-up period was 140 days. During the follow-up period 19/97 (19.6%) hematomas resorbed completely. Moreover, 21/97 (21.6%) of hematomas reduced in size more than 50%; 40 out of 97 embolized hematomas (41.2%) remained stable or were resorbed partially during follow up. Middle meningeal artery embolization failed in 14 cases (14.4%). We noted three cases of asymptomatic hematoma progression (3.1%). Three patients died during follow-up period. No statistically significant difference was shown between primary and recurrent cSDH cohort when compared based on percentage of complete hematoma resolution, treatment failure and rate of hematomas with >50% resorption.ConclusionsMiddle meningeal artery embolization is both safe and feasible stand-alone treatment option for cSDH, primarily for asymptomatic and minimally symptomatic patients with maximal hematoma tickness in the range between 10 and 20 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.